Literature DB >> 498712

Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter.

J Dominic, R G McAllister, C S Kuo, C P Reddy, B Surawicz.   

Abstract

The acute effect of verapamil on the ventricular rate in atrial fibrillation and flutter was studied in 15 patients, 13 of whom had heart rate inadequately controlled with digitalis. Plasma concentrations were measured 5 and 10 min after intravenous doses of 0.075 mg/kg and 0.15 mg/kg verapamil. In 9 patients who were clinically compensated, the 0.075-mg dose alone decreased the ventricular rate to under 100/min (responders); in the remaining 6, who had acute congestive heart failure manifested by orthopnea, rales, and pulmonary congestion, ventricular rates were above 100/min after the 0.075-mg dose (nonresponders). The 6 nonresponders received the 0.15-mg dose 30 min later. In all, the response was greater when plasma drug concentration rose after the high dose, although the rate decrease was smaller than in the 9 compensated patients who received the low dose. These results can be explained by assuming an antagonism of the verapamil effect by sympathetic stimulation in nonresponders.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498712     DOI: 10.1002/cpt1979266710

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

1.  Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers.

Authors:  D N John; S Fort; M J Lewis; D K Luscombe
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

2.  Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.

Authors:  D L Murdoch; G D Thomson; G G Thompson; G D Murray; M J Brodie; G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 3.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

4.  24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation.

Authors:  H Mølgaard; P Bjerregaard; H S Jørgensen; N A Klitgaard
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 5.  Digitalis and verapamil in atrial fibrillation and flutter. Is verapamil now the preferred agent?

Authors:  H O Klein; E Kaplinsky
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

Review 6.  The pharmacologic treatment of atrial fibrillation.

Authors:  R Bolognesi
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

7.  Preliminary investigation of the efficacy of sublingual verapamil in the management of acute atrial fibrillation and flutter.

Authors:  S Fort; M J Lewis; D K Luscombe; D N John
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

Review 8.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

Review 9.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.